ILMN intrinsic value
The tie-up between Illumina (ILMN) and the Broad Institute of MIT and Harvard is expected to enhance the company's portfolio of sequencing products.
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).
The unveiling of Veriseq NIPT v2 and Illumina's (ILMN) alliance with AnchorDx in the second quarter further raise investor confidence in the stock.
Illumina reported earnings per share of $1. 35 on revenue of $838M, the consensus between analysts was $1.34 per share on revenue of $835M.
Shares of Illumina Inc. plummeted 16% in active morning trading Friday, after Bank of America Merrill Lynch swung to being bearish from bullish in the wake. . .
Illumina Inc. shares plunged more than 14% in the extended session Thursday after the company reported preliminary revenue for the fiscal second quarter and. . .
Illumina, Inc. (ILMN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.